Key result
Beta-blockers reduce all-cause mortality, sudden death, and death from worsening heart failure in HFrEF.
Why the study?
Do beta-blockers improve outcomes in patients with heart failure with reduced ejection fraction?
Do beta-blockers improve outcomes in patients with heart failure with reduced ejection fraction?
Beta-blockers are a foundational, dose-dependent therapy that significantly reduces mortality and morbidity in patients with heart failure with reduced ejection fraction.
May support beta-blocker use in HFrEF; leaves open optimal integration with contemporary quadruple therapy.
Betabloktory jsou lky, kter prokazateln ovlivuj prbh srdenho selhn se snenou ejekn frakc lev komory. Betabloktory sniuj celkovou mortalitu, riziko nhl srden smrti a riziko mrt z dvodu zhoren srdenho selhn. Sniuj riziko mrt z kardiovaskulrnch pin a riziko hospitalizac, ovlivuj tedy vznamn i morbiditu nemocnch. Lba je obvykle dobe tolerovna. Je nutn se pokusit vdy doshnout maximln tolerovan dvky, innost je na dvce zvisl. Betabloktory prvem pat do zkladn skupiny lk pro terapii srdenho selhn.
No takes yet. Share an insight, caveat, or question.
Filip Málek (2025) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Beta-blockers was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: